CTMX
CytomX Therapeutics Inc
2.60$
-0.4%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 5.4% | 1.8% | 1.1% | 1.8% | – | 1.1% | – | 1.9% | – | 76.9% | 2.4% | – | – | |
| 94.6% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 97.6% | 100.0% | 98.6% | |
| 39.5% | 72.9% | 53.2% | 100.2% | 63.9% | 38.8% | 37.1% | 71.4% | 256.6% | 3,202.9% | 187.5% | 1,241.0% | 400.9% | |
| 25.8% | 29.4% | 18.7% | 33.4% | 23.8% | 14.8% | 18.5% | 35.5% | 107.8% | 1,110.1% | 104.2% | 536.0% | 175.3% | |
| 52.6% | 102.3% | 71.9% | 133.7% | 87.7% | 53.6% | 55.6% | 106.9% | 364.4% | 4,313.0% | 289.3% | 1,777.1% | 574.8% | |
| 42.0% | -2.3% | 28.1% | -33.7% | 12.3% | 46.4% | 44.4% | -6.9% | -264.4% | -4,213.0% | -191.8% | -1,677.1% | -476.2% | |
| – | 8.8% | – | – | – | – | – | – | – | – | – | – | – | |
| 22.0% | 7.2% | 33.4% | -25.8% | 17.3% | 49.7% | 46.3% | -0.5% | -237.6% | -3,990.3% | -177.3% | -1,453.2% | -434.0% | |
| 10.7% | 4.0% | 0.1% | 0.2% | 0.2% | 0.2% | 0.1% | 0.3% | 1.0% | 8.1% | 0.6% | 4.2% | 1.3% | |
| 11.3% | 3.1% | 33.3% | -26.0% | 17.2% | 49.6% | 46.2% | -0.8% | -238.6% | -3,998.5% | -177.9% | -1,457.4% | -435.2% | |
| 27.4% | 9.0% | 34.5% | -24.0% | 18.6% | 50.8% | 47.1% | 1.4% | -235.4% | -3,913.4% | -174.9% | -1,432.2% | -427.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.